PSIL-006 is the first drug candidate from Psilera’s extensive pipeline to progress into advanced safety studies prior to first-in-human clinical trials TAMPA, Fla., May 25, 2023 /PRNewswire/ — Psilera, a biopharmaceutical company developing next-generation mental health treatments for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.